The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Bristol Myers Squibb to Acquire 2seventy bio for $286M in Abecma Partnership
Mar 11, 2025•over 1 year ago
Contract Type
partnership
CambridgeBiotechnologyHealth CareScience And Engineering
Description
Bristol Myers Squibb (BMS) has announced an agreement to acquire 2seventy bio for approximately $286 million, in a move to solidify their partnership in the development and commercialization of the blockbuster multiple myeloma drug Abecma.
Company Information
Company
2seventy bio
Location
60 BINNEY STREET
Cambridge, Maryland, United States
About
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.
CambridgeBiotechnologyHealth CareScience And Engineering